Geron Co. (NASDAQ:GERN) Shares Acquired by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. boosted its position in Geron Co. (NASDAQ:GERN) by 1.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,523,864 shares of the biopharmaceutical company’s stock after acquiring an additional 73,482 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.75% of Geron worth $16,014,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. SBI Securities Co. Ltd. acquired a new position in Geron in the fourth quarter valued at $28,000. Handelsbanken Fonder AB acquired a new position in Geron in the fourth quarter valued at $601,000. Rhumbline Advisers boosted its holdings in Geron by 1.5% in the fourth quarter. Rhumbline Advisers now owns 834,844 shares of the biopharmaceutical company’s stock valued at $2,955,000 after acquiring an additional 12,070 shares during the last quarter. abrdn plc boosted its holdings in Geron by 24.2% in the fourth quarter. abrdn plc now owns 1,847,285 shares of the biopharmaceutical company’s stock valued at $6,539,000 after acquiring an additional 360,027 shares during the last quarter. Finally, Lazari Capital Management Inc. boosted its holdings in Geron by 11.7% in the fourth quarter. Lazari Capital Management Inc. now owns 76,424 shares of the biopharmaceutical company’s stock valued at $271,000 after acquiring an additional 8,000 shares during the last quarter. Institutional investors and hedge funds own 73.71% of the company’s stock.

Geron Stock Up 2.9 %

Shares of Geron stock opened at $1.75 on Friday. The company has a quick ratio of 2.74, a current ratio of 2.89 and a debt-to-equity ratio of 0.04. The business has a 50-day moving average price of $2.45 and a 200 day moving average price of $3.50. Geron Co. has a fifty-two week low of $1.46 and a fifty-two week high of $5.34. The firm has a market cap of $1.11 billion, a P/E ratio of -5.47 and a beta of 0.53.

Geron (NASDAQ:GERN) last issued its earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) EPS for the quarter, meeting analysts’ consensus estimates of ($0.04). Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The company had revenue of $47.54 million during the quarter, compared to the consensus estimate of $45.29 million. On average, sell-side analysts forecast that Geron Co. will post -0.25 earnings per share for the current fiscal year.

Analysts Set New Price Targets

GERN has been the topic of several research reports. B. Riley lowered Geron from a “buy” rating to a “neutral” rating and cut their price objective for the company from $3.50 to $2.00 in a research report on Thursday, February 27th. Stifel Nicolaus dropped their target price on Geron from $8.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday, February 27th. Scotiabank dropped their target price on Geron from $6.00 to $4.00 and set a “sector outperform” rating on the stock in a research report on Thursday, February 27th. Needham & Company LLC reaffirmed a “buy” rating and set a $5.00 target price on shares of Geron in a research report on Wednesday, March 12th. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of Geron in a research report on Wednesday, March 12th. One analyst has rated the stock with a sell rating, three have given a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Geron presently has an average rating of “Moderate Buy” and an average price target of $5.75.

Geron Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.